Mirtazapine Grindeks (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 receptors while sparing 5‑HT1A. This dual action enhances both noradrenergic and serotonergic neurotransmission, producing an overall antidepressant effect.

The dosage of Mirtazapine Grindeks is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its receptor‑blocking profile, which often results in strong sedative and appetite‑stimulating effects. This can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Store the tablets at room temperature, below 25 °C, in the original container. Protect them from moisture, heat, and direct sunlight to maintain potency throughout the shelf life.

Mirtazapine Grindeks is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe neutropenia, Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy. Patients should be monitored closely for any signs of these conditions.

Mirtazapine is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or those with known hypersensitivity to the drug. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiovascular disease, or a history of severe allergic reactions.